Compare Eli Lilly And Co (LLY) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Toronto-Dominion Bank — how do they compare? Eli Lilly And Co trades at $1,205.29 (market cap $1.08T), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Eli Lilly And Co is far larger — about 5.4× Toronto-Dominion Bank's market cap, and Toronto-Dominion Bank pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| LLY | TD | |
|---|---|---|
Market Cap | $1.08T | $200.48B |
Sector | Health | Financials |
52-Week High | $1.24K | $124.80 |
52-Week Low | $639.43 | $72.85 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
TD trades at $121.08, down 0.19% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive given consistent earnings outperformance and a solid dividend, but risks include high debt levels and volatile cash flows. Analyst consensus is bullish with no sell ratings, supporting a favorable medium-term view amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
